GlassScriptPhysician profile
Kenneth J Herrmann
NPI 1760433536
$42,400.72
in general payments reported to CMS, 2019-2025
31 companies · $8,388 in 2025
The $8,388 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,385 · 2020: $1,205 · 2021: $4,388 · 2022: $6,589 · 2023: $8,004 · 2024: $5,442 · 2025: $8,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $3,423 · Travel and Lodging: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,900.00 |
| Food and Beverage | $3,423.03 |
| Travel and Lodging | $511.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,366.11 | 2021-2025 | |
| Allergan, INC. | $6,543.81 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $3,273.11 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $790.80 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $640.11 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $587.31 | 2019-2022 | |
| Lundbeck LLC | $581.32 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $445.40 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $437.54 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $361.64 | 2019-2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $333.00 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $247.27 | 2019-2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.38 | 2020-2025 | Caplyta |
| Corium, LLC | $203.15 | 2022-2025 | Azstarys |
| Neuronetics, INC. | $180.46 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $164.49 | 2019-2023 | Wellbutrin, Aplenzin |
| Ironshore Pharmaceuticals INC. | $149.15 | 2019-2023 | Jornay Pm |
| Shire North American Group INC | $140.37 | 2019 | |
| Neurocrine Biosciences, INC. | $137.82 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $127.58 | 2023-2025 | Auvelity |
| Adlon Therapeutics L.P. | $104.26 | 2020-2021 | |
| Neos Therapeutics, LP | $99.14 | 2019 | |
| Livanova USA, INC. | $53.84 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Collegium Pharmaceutical, INC. | $47.68 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $42.60 | 2019 | |
| Merck Sharp & Dohme LLC | $27.98 | 2019-2021 | |
| Soleno Therapeutics, INC. | $23.05 | 2025 | Vykat Xr |
| Almatica Pharma LLC | $21.93 | 2023 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $21.42 | 2019 | |
| Bioxcel Therapeutics, INC. | $16.15 | 2024 | Igalmi |
| Azurity Pharmaceuticals, INC. | $12.85 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Herrmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.